Our life-saving therapies are used in trauma and surgical care, and help prevent blood-related diseases in newborns.
ZLB Behring, providing biotherapies for life for more than a century.
|1901||Emil von Behring wins first Nobel Prize in Medicine|
German doctor Emil von Behring wins the first Nobel Prize in Physiology and Medicine for his work on serum therapies. Von Behring’s pioneering work results in the modern methods of immunization that have largely eradicated diphtheria worldwide.
|1904||Emil von Behring creates Behringwerke|
Emil von Behring creates Behringwerke to produce sera and vaccines to combat infectious diseases.
Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
|1940||WWII: Largest supplier of albumin for U.S. military|
Armour becomes the largest supplier of human albumin for the U.S. military during World War II.
|1946||Europe’s first human plasma fractionation|
Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale.
ZLB is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland.
|1951||ZLB mandate to supply blood products|
ZLB receives a mandate from the Swiss government to supply blood products through the Swiss Red Cross Blood Transfusion Service.
|1954||First pasteurized plasma protein solution|
The Zentrallaboratorium Blutspendedienst (ZLB) makes the first pasteurized plasma protein solution.
|1955||Behringwerke researchers discover Alpha-1|
Alpha1-antitrypsin, a proteinase inhibitor, is discovered, purified and characterized for the first time by researchers of Behringwerke.
|1970||Japan’s first IVIg|
Launch of Gamma-Venin®, the first IVIg product in Japan.
|1981||World’s first pasteurized factor VIII therapy|
Haemate® human plasma coagulation factor VIII/von Willebrand factor complex is first marketed in Europe for the treatment of patients with hemophilia A. It is the first pasteurized factor VIII product in the world.
|1984||First IVIg approved in U.S.|
ZLB BTS Swiss Red Cross gets FDA approval for its natural, polyvalent immunoglobulin. This product is the first IVIg preparation to be approved in the United States.
|1986||Humate-P® approved in U.S.|
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for the prevention and control of hemorrhagic episodes in patients with hemophilia A.
|1988||Japan’s first fibrin sealant|
Launch of Beriplast® P, the first fibrin sealant in Japan.
|1993||Helixate® approved in U.S.|
The FDA approves Helixate® recombinant coagulation factor VIII for the treatment of hemophilia A.
|1998||€50 million plant modernization|
Centeon (the predecessor company of Aventis Behring) completes a major, 50 million euro capital project to modernize its production facilities in Marburg, Germany.
|1999||First von Willebrand factor in U.S.|
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for treatment of von Willebrand disease, the most common hereditary bleeding disorder.
|1999||Marburg: State-of-the-art Ig facility|
A state-of-the-art production building for immunoglobulins is built in Marburg, Germany.
|2000||New formulation of recombinant Factor VIII|
Helixate® FS/ Helixate® NexGen recombinant coagulation factor VIII formulated with sucrose for the treatment of hemophilia A. Approved by FDA for use in U.S. and by EMEA for use in 15 countries.
|2000||ZLB Bioplasma established|
CSL acquires ZLB Blood Transfusion Service of Swiss Red Cross to establish ZLB Bioplasma, headquartered in Bern.
|2000||Gettin’ in the Game|
The company launches Gettin’ in the Game, local workshops that promote the value of exercise among children with bleeding disorders.
|2001||ZLB Plasma Services established|
CSL acquires 47 plasma collection centers and laboratory facilities operated by Nabi Plasma Collection Centers (U.S.) and creates ZLB Plasma Services.
|2001||World’s largest plasma collection business|
Aventis Behring acquires 42 plasma centers from Seralogicals, forming the world’s largest plasma collection business.
The company establishes a foundation for research and advancement of patient health—the only non-profit foundation dedicated exclusively to charitable, scientific and educational endeavors that benefit the bleeding disorders community.
|2002||Rhophylac® launched in Germany|
Rhophylac® human anti-D immunoglobulin is launched in Germany.
|2002||Junior National Championships|
The company launches Junior National Championships in partnership with the National Hemophilia Foundation to promote the value of exercise for children with bleeding disorders.
|2003||Carimune® NF launched in U.S.|
The company begins marketing Carimune® NF human normal immunoglobulin for intravenous (IV) administration in the United States.
|2003||Zemaira® approved in U.S.|
FDA approves Zemaira® human alpha1-proteinase inhibitor for individuals with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema.
|2003||Assurance Program launched|
The Assurance Program is launched to ensure that people who rely on our recombinant and plasma-derived therapies can continue to receive these vital treatments even if they experience a lapse in third-party, private health insurance.
|2004||ZLB Behring established|
CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring.
|2004||EMEA approves Mononine®|
The EMEA approves Mononine® human coagulation factor IX concentrate for the treatment of hemophilia B patients undergoing surgery, exposed to trauma, or experiencing severe, spontaneous hemorrhage. The company becomes the first to market a factor IX product approved for this method of treating these indications.
|2004||Rhophylac® approved in U.S.|
ZLB’s Rhophylac® human anti-D immunoglobulin is approved by the FDA.
ZLB Behring introduces the Mix2Vial™ alternate transfer device, a new way to reconstitute products.
|2006||Groundbreaking: state-of-the-art Ig plant|
Construction begins on a new immunoglobulin manufacturing plant at ZLB Behring’s Bern, Switzerland, facility.
|2006||Vivaglobin® approved in U.K.|
Vivaglobin® licensed for use in the U.K. in adults and children who require antibody replacement due to primary immunodeficiency.
|2006||State-of-the-art plant licensed by FDA|
Highly automated facility in Kankakee, Illinois to allow for increased production of Zemaira®.
|2006||Vivaglobin® first SCIg in U.S.|
U.S. Food and Drug Administration (FDA) grants marketing approval for Vivaglobin® human normal immunoglobulin for subcutaneous administration. Vivaglobin is the first FDA-approved subcutaneous immunoglobulin (SCIg) treatment.
|2006||Humate-P® 50% volume reduction|
Humate-P® human coagulation factor VIII/von Willebrand factor complex is now available featuring a smaller diluent—50 percent less in all assay sizes, shortening infusion time and requiring less storage space.
|ZLB Behring continues to build on this legacy of innovation and patient care.|